Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash & Equivalents (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Cash & Equivalents for 11 consecutive years, with $64.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 45.07% to $64.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $64.8 million, a 45.07% increase, with the full-year FY2025 number at $64.8 million, up 45.07% from a year prior.
  • Cash & Equivalents was $64.8 million for Q4 2025 at Niagen Bioscience, up from $64.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $64.8 million in Q4 2025 to a low of $13.3 million in Q3 2022.
  • A 5-year average of $34.9 million and a median of $28.1 million in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 228.48% in 2021, then tumbled 59.94% in 2022.
  • Niagen Bioscience's Cash & Equivalents stood at $28.2 million in 2021, then dropped by 27.56% to $20.4 million in 2022, then soared by 33.68% to $27.3 million in 2023, then skyrocketed by 63.44% to $44.7 million in 2024, then skyrocketed by 45.07% to $64.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Cash & Equivalents are $64.8 million (Q4 2025), $64.3 million (Q3 2025), and $60.5 million (Q2 2025).